Glucagon-Like Peptide-1 Receptor

A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).

Also Known As:

Networked: 1974 relevant articles (180 outcomes, 343 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Drucker, Daniel J: 32 articles (11/2021 - 09/2005)
2.	Holst, Jens J: 25 articles (01/2022 - 08/2009)
3.	Knop, Filip K: 25 articles (01/2022 - 08/2009)
4.	Vilsbøll, Tina: 25 articles (01/2022 - 05/2010)
5.	Rosenstock, Julio: 23 articles (01/2022 - 10/2009)
6.	Hayes, Matthew R: 16 articles (11/2021 - 03/2011)
7.	Wild, Damian: 15 articles (06/2022 - 12/2006)
8.	Buse, John B: 15 articles (04/2021 - 07/2009)
9.	Madsbad, Sten: 15 articles (01/2020 - 02/2015)
10.	Seino, Yutaka: 14 articles (01/2021 - 02/2008)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2010 - "This new, once-daily GLP-1 receptor agonist shows promise in the management of Type 2 diabetes to be defined further by ongoing long-term studies." 10/01/2021 - "Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial." 10/01/2023 - "In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed current guidelines and improved outcomes for individuals with type 2 diabetes. " 12/01/2023 - "To our knowledge, this is the first real-world study to investigate the safety and effectiveness of a glucagon-like peptide-1 receptor agonist in Chinese patients with type 2 diabetes mellitus (T2DM). " 11/01/2023 - "Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study."
2.	Obesity 01/01/2018 - "GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis." 11/02/2023 - "Agonists of the glucagon-like peptide-1 receptor (GLP-1R) are used to treat diabetes and obesity. " 10/09/2023 - "The glucagon-like peptide-1 receptor (GLP-1R) is a validated target for the treatment of diabetes and obesity, but drugs that target this receptor are a frequent cause of adverse events. " 06/01/2023 - "Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce food intake and are FDA-approved for treating obesity. " 01/01/2023 - "Food and Drug Administration-approved glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat obesity require complete characterization of the central mechanisms that mediate both the food intake-suppressive and illness-like effects of GLP-1R signaling. "
3.	Body Weight (Weight, Body) 12/01/2023 - "Treatment with either glucagon-like peptide-1 receptor agonist yielded similar and clinically meaningful reductions in HbA1c and body weight." 09/15/2023 - "In recent years, drugs activating the glucagon-like peptide-1 receptor (GLP-1R) pathway have proved to achieve significant reductions in body weight with a favorable safety profile. " 01/01/2021 - "Through activation of the GLP-1 receptor they not only have an important role stimulating insulin secretion after meals, but with their extrapancreatic actions, both peripheral and central, they also help reduce body weight by promoting satiety and delaying gastric emptying. " 03/01/2014 - "GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents." 02/01/2014 - "Although Ex (9-39) administration did not significantly affect food consumption, it resulted in a marked body weight gain, indicating that the GLP-1 receptor antagonist caused a positive energy balance. "
4.	Weight Loss (Weight Reduction) 07/10/2023 - "Research has shown that the metabolic features of PCOS may be improved by weight loss following treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists. " 01/01/2022 - "Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss." 11/11/2021 - "Glucagon-like peptide 1 receptor agonist (GLP1-RA) present a novel option to treat this dual disease by their salutary effects on glycaemic control and weight reduction. " 06/01/2021 - "Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?" 01/01/2021 - "Consequently, this pharmacological approach, in combination with novel Gipr mouse models, has provided evidence indicating that activation of GIPR in certain areas of the brain that regulate energy balance is required for the synergistic weight loss of dual GIPR and GLP-1 receptor (GLP-1R) agonism. "
5.	Inflammation (Inflammations) 12/01/2022 - "miR-21-5p aggravates type 2 inflammation in the nasal mucosa of patients with CRSwNP via targeting glucagon-like peptide-1 receptor/IL-33 signaling, which may be a potential therapeutic target for CRSwNP." 11/01/2021 - "Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice." 07/01/2015 - "Furthermore, islet viability, apoptosis, oxidative stress and inflammation, as well as islet structure were assessed after altering GLP-1 receptor signaling. " 09/01/2014 - "The extent to which the intrarenal DPP-4/GLP-1 receptor system contributes to all these changes remains to be established, as does the direct impact of the system on renal inflammation. " 01/01/2023 - "Beyond glycemic control, applications of glucagon-like peptide-1 receptor (GLP-1r) agonists (GLP-1 RAs) inhibit inflammation and plaque development in murine atherosclerotic models. "

Related Drugs and Biologics

1.	Liraglutide
2.	Exenatide (Byetta)
3.	Insulin (Novolin)
4.	Glucose (Dextrose)
5.	Glucagon-Like Peptide 1 (GLP 1)
6.	semaglutide
7.	dulaglutide
8.	Sodium-Glucose Transporter 2 Inhibitors
9.	lixisenatide
10.	Hypoglycemic Agents (Hypoglycemics)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Injections
4.	Subcutaneous Injections
5.	Caloric Restriction